The US Food and Drug Administration (FDA) has approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. ALS is a rare, progressive disease that attacks and kills the nerve cells that control voluntary muscles, which produce movements such as chewing, walking, breathing, and talking. Most people with ALS die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. Radicava is manufactured by Mitsubishi Tanabe Pharma America, Inc., headquartered in Jersey City, NJ.
Indications: Radicava is an intravenous infusion given by a health care professional. It is administered with an initial treatment cycle of daily dosing for 14 days, followed by a 14-day drug-free period. Subsequent treatment cycles consist of dosing on 10 of 14 days, followed by 14 days drug-free.
Dosage/administration: The recommended dosage is 60 mg administered as an intravenous infusion over 60 minutes.
Adverse effects: Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.
US Food and Drug Administration. FDA approves drug to treat ALS. FDA Web site. May 5, 2017. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm557102.htm. Accessed May 16, 2017.
Must Reads in FDA Actions
FDA Approves Inbrija for PD OFF Episodes, Acorda Therapeutics news release; 2018 Dec 21
FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28
FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14
FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6
FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23